Buscar resultados de ensayos clínicos
Lymphoma, Large-Cell, Anaplastic - 25 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma Condición:
Intervenciones: Drug: brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion |
Completed |
Nombre del estudio: Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma Condición: Anaplastic Large-Cell Lymphoma Fecha: 2004-03-12 Intervenciones: Drug: SGN-30 (anti-CD30 mAb) |
Terminated |
Nombre del estudio: SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma Condición: Anaplastic Large Cell Lymphoma Fecha: 2006-08-16 Intervenciones:
|
Withdrawn |
Nombre del estudio: A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib Condición: Systemic Anaplastic Large-Cell Lymphoma Fecha: 2015-06-30 Intervenciones: Drug: crizotinib crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vinc |
Active, not recruiting |
Nombre del estudio: Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Condición: Anaplastic Large-cell Lymphoma Fecha: 2013-07-01 Intervenciones: Drug: brentuximab vedotin Brentuximab vedotin will be administered as a single intravenous (IV) infusion |
Recruiting |
Nombre del estudio: Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) Condición:
Fecha: 2016-10-18 Intervenciones: Drug: Brentuximab Vedotin Brentuximab vedotin IV infusion. |
Terminated |
Nombre del estudio: Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma Condición:
|
Not yet recruiting |
Nombre del estudio: Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma Condición:
|
Recruiting |
Nombre del estudio: Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma" Condición: Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma Fecha: 2014-04-17 Intervenciones: Drug: Brentuximab vedotin (recombinant) Brentuximab vedotin (recombinant) for IV infusion |
Completed |
Nombre del estudio: A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma Condición:
Fecha: 2013-09-23 Intervenciones:
|